Dr. Rouleau began his appointment as Director of The Neuro on January 1, 2013. Since arriving, Dr. Rouleau has been creating a framework for The Neuro of the future by creating new collaborations and reinforcing the lines of communication between the bench and the bedside.
Previously, he was Director of the CHU Ste-Justine Research Centre and founder and Director of the Centre of Excellence in Neuroscience at Université de Montréal. There he held the Canada Research Chair in Genetics of the Nervous System as well as the Jeanne-et-J.-Louis-Levesque Chair in Genetics of Brain Diseases. Dr. Rouleau obtained his MD (Magna Cum Laude) in 1980 from the University of Ottawa and his PhD in Genetics from Harvard University in 1989. His post-graduate research in neuroscience was conducted at the Montreal Neurological Institute and at Massachusetts General Hospital. Dr. Rouleau conducted his clinical training in internal medicine at the Montreal General Hospital, his neurology residency at the Montreal Neurological Institute, and his research fellowship at the Massachusetts General Hospital.
Dr. Rouleau’s landmark achievements are his contributions to the identification of more than 20 disease-causing genes and his discovery of new mutational mechanisms. Over the last 25 years, Dr. Rouleau and his team have focused on understanding the genetic basis for diseases and identifying genes causing neurological and psychiatric diseases including amyotrophic lateral sclerosis, stroke, essential tremor, familial aneurysms, cavernous angiomas, epilepsy, spinocerebellar ataxia, spastic paraplegia, autism, Tourette syndrome, restless legs syndrome, schizophrenia and bipolar disorder. He has published more than 600 articles in top peer-reviewed journals such as The Lancet, Cell, and Nature, as well as 50 review articles and book chapters. His work has been cited over 30,000 times. He has delivered more than 150 lectures around the world. He has supervised many students (10 Master’s, 40 PhD, and 44 post-doctoral fellows). Many of his former students are now professors at universities in Brazil, France, Portugal, Japan, the USA and Canada.
Dr. Rouleau has received numerous awards, including the 2016 Prix de l’oeuvre scientifique from the Médecins francophones du Canada, the 2014 Prix d’Excellence du Collège des Médecins du Québec and the 2012 Prix du Québec – Prix Wilder Penfield, the 2012 Margolese National Brain Disorders Prize from the University of British Columbia, and the Henry Friesen Prize from the Royal College of Physicians and Surgeons of Canada / The Canadian Society for Clinical Investigation. He is an Officer of the Ordre national du Québec and a fellow of the Royal Society of Canada (2016).
Dr. Rouleau sits on the editorial boards of major scientific journals including Neurology of Disease and Annals of Human Genetics, and performs ad hoc reviews for more than 25 journals. He also serves on several international scientific boards including the IGBMC Strategic Scientific Advisory Board, Strasbourg, France and is a board member of several foundations and societies dedicated to finding cures for nervous system diseases, including the Jumelles Coudé foundation, Ataxia of Charlevoix-Saguenay Foundation, Gairdner Medical Advisory Board, the Cole Foundation and the Canadian Academy of Health Sciences. Dr. Rouleau has also served on the panel for numerous grant committees (ex. CIHR, NIH, ALSA, ENR, NNFF, FRQS). He has founded and directed several successful companies including RGS Genome Inc., Xenon Genetics Research Inc., and Emerillon Therapeutics Inc.